Advanced Solid Malignancies
Conditions
Keywords
Advanced cancer, Solid tumour, Solid malignancies, Neoplasms
Brief summary
The main purpose of this study is to explore the safety and tolerability of multiple ascending doses (MAD) of AZD8931 in patients with advanced solid malignancies
Interventions
DRUGAZD8931
Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
Sponsors
AstraZeneca
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Cancer which is refractory to standard therapies, or for which no standard therapies exist. Inclusion is irrespective of stage of disease or extent of prior therapy. * Histologically or cytologically confirmed solid, malignant tumour.
Exclusion criteria
* Receipt of any of the following treatments within 4 weeks prior to study entry: chemotherapy (within 6 weeks for nitrosurea or mitomycin C), radiotherapy, hormone therapy (except for androgen-deprivation therapy for patients with prostate cancer), immunotherapy and any other anti-cancer therapies. * Unresolved toxicity (other than stable toxicity) from previous anti-cancer therapy, except alopecia. * History of documented cardiac failure, angina pectoris requiring antianginal medication, evidence of transmural infarction on ECG, poorly controlled hypertension (systolic \>180 mmHg or diastolic \>100 mmHg), significant valvular disease or history of high risk dysrrhythmia (such as ventricular fibrillation or ventricular tachycardia \[includes ventricular triplets\]). * Resting ECG with measurable QTc interval of \> 460 msec at 2 or more time-points within a 24-hour time period, or history of prolonged QTc syndrome. * The presence of any ocular disease or condition that is active or is likely to flare up during the course of the study or any systemic disease/condition that is affecting or has affected the eye in the past and may flare up, or the treatment of which may have an adverse effect on the eye. Eye conditions that are stable and of long standing, such as scars from trauma, pinguecula, atrophic pterygia etc, should not be considered as reasons to exclude the patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Explore the safety and tolerability of multiple ascending doses (MAD) of AZD8931 in patients with advanced solid malignancies, by assessment of AEs, lab findings, physical examinations, vital signs, cardiac monitoring and ophthalmological examinations | — |
Secondary
| Measure | Time frame |
|---|---|
| To explore the pharmacokinetics (PK) of single doses of AZD8931 in patients with advanced solid malignancies | — |
| To explore the pharmacokinetics (PK) of multiple doses of AZD8931 in patients with advanced solid malignancies | — |
| To identify the maximum tolerated dose (MTD) of AZD8931 following repeated twice daily administration, by assessment of dose limiting toxicities (DLT) | — |
Countries
Germany, Russia
Outcome results
None listed